Virpax Posts Toxicology, Pharmacokinetic Data For Pain Med Epoladerm

Virpax Pharmaceuticals Inc VRPX reported results following toxicology and pharmacokinetic study of Epoladerm to manage pain associated with osteoarthritis of the knee.
Charles River Laboratories International Inc CRL, CRO engaged by Virpax, completed the study in minipigs as part of the required Investigational New Drug Application enabling trials.
Single-dose transdermal delivery of Epoladerm was well-tolerated in all minipigs, and no treatment-related clinical observations, changes in body weight, or dermal irritation were observed.
All Epoladerm treated animals had plasma levels of Epoladerm confirming transdermal absorption.
The maximum plasma concentration (Cmax) was reached at 4 hours post-dose, and plasma Epoladerm remained at 24-hour post-dose for all animals.
Virpax Pharmaceuticals is developing Epoladerm (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film.
Price Action: VRPX shares are up 1.48% at $4.11 during the market session on the last check Wednesday.